March 27, 2025 From Musician to Physician to Clinical Scientist: C-Path CEO Klaus Romero Shares His Journey During National Physicians Week Every year, National Physicians Week is celebrated from March 25-31, a time to honor the dedication and resilience of our...
March 25, 2025 Breaking Down Research: Investigation of Urinary miRNAs for Early Detection of Kidney Damage in selected lab animals Drug-induced kidney injury is commonly identified during drug development and serves as a dose-limiting factor...
March 24, 2025 Lysosomal Storage Disease Data Sharing Workshop, Webinar Series Session #2: Case Studies #1 – Proactive Data Sharing This webinar from Critical Path Institute's Critical Path to Lysosomal Diseases Consortium presents...
April 17, 2025 ACE Inhibitors as a Cardioprotective Treatment in Dystrophinopathies ACE inhibitors were the first pharmacological class shown to benefit heart failure treatment...
February 26, 2025 Transforming Data into Breakthroughs: 5 Years of RDCA-DAP Journey and Impact In honor of Rare Disease Month, Alexandre Bétourné took some time to sit down and discuss the impact RDCA-DAP has made...
February 24, 2025 Lysosomal Storage Disease Data Sharing Workshop, Webinar Series – Session #1: Setting the Scene C-Path's CPLD team presents, "Lysosomal Storage Disease Data Sharing Workshop, Webinar Series - Session #1...
February 19, 2025 Advancing Neonatal Drug Development Through Collaboration At C-Path’s INC, we believe that meaningful progress in neonatal drug development...
February 19, 2025 C-Path’s eCOA Consortium Welcomes Veeva Systems and VPG Health as Newest Partners C-Path's eCOA Consortium is thrilled to welcome Veeva Systems and VPG Health...
January 28, 2025 TRxA Funding Opportunities 2025 On January 28, C-Path’s Translational Therapeutics Accelerator (TRxA)...
February 20, 2025 Vivli and RDCA-DAP Present: Data Platform Partnerships to promote Rare Disease Data Sharing Join Julie Wood, Chief Operating Officer at Vivli, for an engaging webinar, Thursday, February 20, where she’ll discuss...
